An unnamed strategic investor has contributed to the Johnson & Johnson-backed medical device producer's latest round.
NeuroPace, a US-based epilepsy treatment device developer backed by pharmaceutical firm Johnson & Johnson, collected $67m on Monday in a funding round led by private equity fund Accelmed Partners.
The round featured an undisclosed strategic investor as well as Revelation Partners, Soleus Capital, KCK Group and Orbimed Advisors. It consisted of $33m in new equity financing and $34m of debt from an earlier round converted into equity.
The company could potentially receive up to $27m in additional funding that is…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
